Japan’s Takeda Cleared To Sell Velcade As Early Blood Cancer Drug
This article was originally published in PharmAsia News
The U.S. FDA cleared Takeda Pharmaceutical for expanded use of its Velcade (bortezomib) cancer drug as treatment for newly diagnosed multiple myeloma patients. The drug previously had been allowed only for patients who had been treated with other drugs. Takeda acquired the drug, which was co-developed by Johnson & Johnson, in its acquisition of Millennium Pharmaceuticals. With the new indication, Velcade is expected to become a competitor for Celgene's Thalomid (thalidomide). (Click here for more
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.